⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
prnewswire.com
LLY
MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online — 2026 Search Trends and Publicly Available Pricing Information Context
globenewswire.com
LLY
Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
globenewswire.com
ABBV
AZN
BIIB
BMY
GSK
LLY
MRK
NVS
SNY
TEVA
UCB
SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts
globenewswire.com
GILD
LLY
AMGN
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
globenewswire.com
MGTX
LLY
T. ROWE PRICE EXPLORES LEADERSHIP, TRANSFORMATION, AND THE FUTURE OF MOBILITY WITH FORD CEO JIM FARLEY
prnewswire.com
TROW
F
GE
NYT
ISRG
NVDA
XOM
CRH
LLY
TMUS
Power and Paradox: Value of Leading US Brands Rises to $6.44 Trillion as Global Trust Weakens
businesswire.com
AAPL
MSFT
GOOGL
GOOG
HBAN
BAH
LLY
BEN
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
accessnewswire.com
LEXX
LLY
NVO
PFE
Accelerating GLP-1 Peptides to Market Through Integrated Formulation & Analytical Development, Upcoming Webinar Hosted by Xtalks
prnewswire.com
NVO
LLY
Form Health Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
businesswire.com
LLY
NVO